Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection†
Corresponding Author
Peter Hraber
From Theoretical Biology & Biophysics, Los Alamos National Laboratory, Los Alamos, NM
fax: 505-665-3493
Theoretical Biology & Biophysics, T-10, MS K710, Los Alamos National Laboratory, P.O. Box 1663, Los Alamos, NM 87545===Search for more papers by this authorCarla Kuiken
From Theoretical Biology & Biophysics, Los Alamos National Laboratory, Los Alamos, NM
Search for more papers by this authorKarina Yusim
From Theoretical Biology & Biophysics, Los Alamos National Laboratory, Los Alamos, NM
Search for more papers by this authorCorresponding Author
Peter Hraber
From Theoretical Biology & Biophysics, Los Alamos National Laboratory, Los Alamos, NM
fax: 505-665-3493
Theoretical Biology & Biophysics, T-10, MS K710, Los Alamos National Laboratory, P.O. Box 1663, Los Alamos, NM 87545===Search for more papers by this authorCarla Kuiken
From Theoretical Biology & Biophysics, Los Alamos National Laboratory, Los Alamos, NM
Search for more papers by this authorKarina Yusim
From Theoretical Biology & Biophysics, Los Alamos National Laboratory, Los Alamos, NM
Search for more papers by this authorPotential conflict of interest: Nothing to report.
Abstract
Outcomes of infection with hepatitis C virus (HCV) vary widely, from asymptomatic clearance to chronic infection, leading to complications that include fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure. Previous studies have reported statistical associations between human leukocyte antigen (HLA) heterozygosity and favorable outcomes of infection with either hepatitis B virus (HBV) or human immunodeficiency virus (HIV) (the “heterozygote advantage”). To investigate whether HLA zygosity is associated with outcome of HCV infection, we used data from the United States Organ Procurement and Transplantation Network database of 52,435 liver transplant recipients from 1995 through 2005. Of these, 30,397 were excluded for lack of HLA data, retransplantation, known HIV infection, or insufficient information regarding HBV infection. The remaining cases were analyzed for associations between HCV infection and HLA zygosity with 1-sided Fisher's exact tests. Results show significantly lower proportions of HLA-DRB1 heterozygosity among HCV-infected than uninfected cases. The differences were more pronounced with alleles represented as functional supertypes (P = 1.05 × 10−6) than as low-resolution genotypes (P = 1.99 × 10−3). No significant associations between zygosity and HCV infection were found for other HLA loci. Conclusion: These findings constitute evidence for an advantage among carriers of different supertype HLA-DRB1 alleles against HCV infection progression to end-stage liver disease in a large-scale, long-term study population. Considering HLA polymorphism in terms of supertype diversity is recommended in strategies to design association studies for robust results across populations and in trials to improve treatment options for patients with chronic viral infection. Access to deidentified clinical information relating genetic variation to viral infection improves understanding of variation in infection outcomes and might help to personalize medicine with treatment options informed in part by human genetic variation. (HEPATOLOGY 2007.)
REFERENCES
- 1 Shoukry NH, Cawthon AG, Walker CM. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol 2004; 58: 391–424.
- 2 Elliot LN, Lloyd AR, Ziegler JB, Ffrench RA. Protective immunity against hepatitis C virus infection. Immunol Cell Biol 2006; 84: 239–249.
- 3 Martin MP, Carrington M. Immunogenetics of viral infections. Curr Opin Immunol 2005; 17: 510–516.
- 4 Janeway CA, Travers P, Walport M, Shlomchik MJ. Immunobiology: The Immune System in Health and Disease. 6th ed. New York, NY: Garland Science, 2005.
- 5 Gremion C, Cerny A. Hepatitis C virus and the immune system: a concise review. Rev Med Virol 2005; 15: 235–268.
- 6 Marsh SGE, Parham P, Barber LD. The HLA FactsBook. San Diego, CA: Academic Press, 2000.
- 7 Thursz M. MHC and the viral hepatitides. Q J Med 2001; 94: 287–291.
- 8 Piertney SB, Oliver MK. The evolutionary ecology of the major histocompatibility complex. Heredity 2006; 96: 7–21.
- 9 Buus S. Description and prediction of peptide-MHC binding: the “human MHC project. ” Curr Opin Immunol 1999; 11: 209–213.
- 10 Cox AL, Mosbruger T, Mao Q, Liu Z, Wang XH, Yang HC, et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 2005; 201: 1741–1752.
- 11 Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999; 50: 201–212.
- 12 Doytchinova IA, Flower DR. In silico identification of supertypes for class II MHCs. J Immunol 2005; 174: 7085–7095.
- 13 Thursz MR, Thomas HC, Greenwood BM, Hill AVS. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet 1997; 17: 11–12.
- 14 Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999; 283: 1748–1752.
- 15 Navarro V, Herrine S, Katopes C, Colombe B, Spain CV. The effect of HLA class I (A and B) and class II (DR) compatibility on liver transplantation outcomes: an analysis of the OPTN database. Liver Transpl 2006; 12: 652–658.
- 16 Shiffman ML, Saab S, Feng S, Abecassis MI, Tzakis AG, Goodrich NP, et al. Liver and intestine transplantation in the United States, 1995-2004. Am J Transplant 2006; 6: 1170–1187.
- 17 Williams TM. Human leukocyte antigen gene polymorphism and the histocompatibility laboratory. J Mol Diagn 2001; 3: 98–104.
- 18 Racanelli V, Rehermann B. Hepatitis C virus infection: when silence is deception. Trends Immunol 2003; 24: 456–464.
- 19 Thimme R, Lohmann V, Weber F. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res 2006; 69: 129–141.
- 20 Motulsky H. Intuitive Biostatistics. Oxford, UK: Oxford University Press, 1995.
- 21 Storey JD, Tibshirani R. Statistical significance for genome-wide experiments. Proc Natl Acad Sci U S A 2003; 100: 9440–9445.
- 22 Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immun 2004; 5: 237–245.
- 23 Harcourt G, Hellier S, Bunce M, Satsangi J, Collier J, Chapman R, et al. Effect of HLA class II genotype on T helper lymphocyte responses and viral control in hepatitis C virus infection. J Viral Hepat 2001; 8: 174–179.
- 24 Zavaglia C, Bortolon C, Ferrioli G, Rho A, Mondazzi L, Botelli R, et al. HLA typing in chronic type B, D, and C hepatitis. J Hepatol 1996; 24: 658–665.
- 25 Fanning LJ, Levis J, Kenny-Walsh E, Wynne F, Whelton M, Shanahan F. Viral clearance in hepatitis C (1b) infection: relationship with human leukocyte antigen class II in a homogeneous population. HEPATOLOGY 2000; 31: 1334–1337.
- 26 Vejbaesya S, Songsivilai S, Tanwandee T, Rachaibun S, Chantangpol R, Dharakul T. HLA association with hepatitis C virus infection. Hum Immunol 2000; 61: 348–353.
- 27 Wang L-Y, Lin HH, Lee T-D, Wu Y-F, Hu C-T, Cheng M-L, et al. Human leukocyte antigen phenotypes and hepatitis C viral load. J Clin Virol 2005; 32: 144–150.
- 28 Zavaglia C, Martinetti M, Silini E, Bottelli R, Daielli C, Asti M, et al. Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C. J Hepatol 1998; 28: 1–7.
- 29 Patel K, Norris S, Lebeck L, Feng A, Clare M, Pianko S, et al. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. HEPATOLOGY 2006; 43: 241–249.
- 30 Belli LS, Zavaglia C, Alberti AB, Poli F, Rondinara G, Selini E, et al. Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation. HEPATOLOGY 2000; 31: 1345–1350.
- 31 Seeff LB. Natural history of chronic hepatitis C. HEPATOLOGY 2002; 26: S35–S46.
- 32 Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450–456.
- 33 Fanning LJ, Levis J, Kenny-Walsh E, Whelton M, O'Sullivan K, Shanahan F. HLA class II genes determine the natural variance of hepatitis C viral load. HEPATOLOGY 2001; 33: 224–230.
- 34 Bakr I, Rekacewicz C, Hosseiny ME, Ismail S, Daly ME, El-Kafrawy S, et al. Higher clearance of HCV infection in females compared with males. Gut 2006; 55: 1183–1187.
- 35 Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13: 34–41.
- 36 De Groot A, Jesdale B, Martin W, Saint Aubin C, Sbai H, Bosma A, et al. Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach. Vaccine 2003; 21: 4486–4504.
- 37 Asti M, Martinetti M, Zavaglia C, Cuccia MC, Gusberti L, Tinelli C, et al. Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease. HEPATOLOGY 1999; 29: 1272–1279.
- 38 Thio CL, Gao X, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol 2002; 76: 4792–4797.
- 39 Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872–874.
- 40 McKiernan SM, Hagan R, Curry M, McDonald GSA, Kelly A, Nolan N, et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. HEPATOLOGY 2004; 40: 108–114.
- 41 Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangenberg HC, Killinger T, et al. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. HEPATOLOGY 2006; 43: 563–572.
- 42 Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004; 432: 769–774.
- 43 Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PT, Hayes E, et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med 2003; 9: 928–935.
- 44 Yunis EJ, Larsen CE, Fernandez-Viña M, Awdeh ZL, Cao K, Romero T, et al. Human MHC haplotypes and their fragments or blocks. In: JA Hansen, ed. Immunobiology of the Human MHC: 13th International Histocompatibility Workshop and Congress. Volume 1. Victoria, British Columbia, Canada: International Histocompatibility Working Group Press, 2006: 54–64.
- 45 Maiers M, Gragert L, Klitz W. High-resolution HLA alleles and haplotypes in the United States population. Hum Immunol (in press).
- 46 Stephens HA. HIV-1 diversity versus HLA class I polymorphism. Trends Immunol 2005; 26: 41–47.
- 47 Nolan D, Gaudieri S, Mallal S. Host genetics and viral infections: immunology taught by viruses, virology taught by the immune system. Curr Opin Immunol 2006; 18: 413–421.
- 48 Korber B, LaBute M, Yusim K. Immunoinformatics comes of age. PLoS Comput Biol 2006; 2: e71.
- 49 Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics 2005; 21: 379–384.
- 50 Kuiken C, Mizokami M, Deleage G, Yusim K, Penin F, Shin-I R, et al. Hepatitis C databases, principles, and utility to researchers. HEPATOLOGY 2006; 43: 1157–1165.
- 51 Yusim K, Richardson R, Tao N, Dalwani A, Agrawal A, Szinger J, et al. Los Alamos hepatitis C immunology database. Appl Bioinformatics 2005; 4: 217–225.
- 52 Levine GN, McCullough KP, Rodgers AM, Dickinson DM, Ashby VB, Schaubel DE. Analytical methods and database design: implications for transplant researchers, 2005. Am J Transplant 2006; 6: 1228–1242.
